BridgeMD
New treatment option for Dilated Cardiomyopathy
Official title Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age
ClinicalTrials.gov ID: NCT06250257
What this study is testing
What is Bromocriptine mesylate plus standard GDMT?
Bromocriptine mesylate plus standard GDMT is an investigational medicine, given as an once-daily, being studied as a potential treatment for dilated cardiomyopathy.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Dilated cardiomyopathy (DCM) is a condition associated with left and /or right ventricular (LV) dilatation and systolic dysfunction without coronary artery disease or abnormal loading circumstances proportionate to the severity of LV impairment. It is one of the leading causes of heart failure in younger adults.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 50, women only
You may be able to join if
- Women age 18 years to 50 years and
- ischemic or de novo dilated cardiomyopathy
You likely can't join if
- Patients with severe comorbidities which may worsen their illness
- with hypertensive heart diseases
- Rheumatic valvular heart diseases
- Restrictive cardiomyopathy, constrictive cardiomyopathy, hypertrophic cardiomyopathy
- Congenital heart diseases
- Acute coronary syndrome
See the full eligibility criteria
- Women age 18 years to 50 years and
- ischemic or de novo dilated cardiomyopathy
- Patients with severe comorbidities which may worsen their illness
- with hypertensive heart diseases
- Rheumatic valvular heart diseases
- Restrictive cardiomyopathy, constrictive cardiomyopathy, hypertrophic cardiomyopathy
- Congenital heart diseases
- Acute coronary syndrome
- Overt kidney failure (serum Creatinine ≥ 1.4mg/dl),
- Women who had history of peripartal cardiomyopathy, are pregnant or planning pregnancy during the study period or lactating
- Previous adverse reaction to the bromocriptine
- Patients not willing to participate in the study
The study team makes the final eligibility decision.
Where it's taking place
- Jimma, Oromiya, Ethiopia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 50 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Jimma, Oromiya, Ethiopia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.